



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/521,640	03/10/2000	Joseph R Byrum	04983.0120.usol/38-21(157	9889
28381	7590	05/04/2006	EXAMINER	
ARNOLD & PORTER LLP ATTN: IP DOCKETING DEPT. 555 TWELFTH STREET, N.W. WASHINGTON, DC 20004-1206			BORIN, MICHAEL L	
			ART UNIT	PAPER NUMBER
			1631	

DATE MAILED: 05/04/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

**Office Action Summary**

Application No.

09/521,640

Applicant(s)

BYRUM ET AL.

Examiner

Michael Borin

Art Unit

1631

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --  
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

**Status**

- 1) ☒ Responsive to communication(s) filed on 25 December 2005.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

**Disposition of Claims**

- 4) ☒ Claim(s) 23-27 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 23-27 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

**Application Papers**

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

**Priority under 35 U.S.C. § 119**

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some \* c) ☐ None of:
- ☐ Certified copies of the priority documents have been received.
  - ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  - ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- \* See the attached detailed Office action for a list of the certified copies not received.

**Attachment(s)**

- ☐ Notice of References Cited (PTO-892)
- ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- ☐ Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)  
Paper No(s)/Mail Date \_\_\_\_\_
- ☐ Interview Summary (PTO-413)  
Paper No(s)/Mail Date. \_\_\_\_\_
- ☐ Notice of Informal Patent Application (PTO-152)
- ☐ Other: \_\_\_\_\_

### **DETAILED ACTION**

1. A request for continued examination under 37 CFR 1.114 was filed in this application after appeal to the Board of Patent Appeals and Interferences, but prior to a decision on the appeal. Pursuant to applicant's Request for Continued Examination, the Board of Patent Appeals and Interferences has dismissed the appeal.

Since this application is eligible for continued examination under 37 CFR 1.114 and the fee set forth in 37 CFR 1.17(e) has been timely paid, the appeal has been withdrawn pursuant to 37 CFR 1.114 and prosecution in this application has been reopened pursuant to 37 CFR 1.114. Applicant's submission filed on 12/25/2005 has been entered.

### ***Status of claims***

2. Claims 1-22 are canceled. Claims 23-27 are pending.
3. The instant claims are directed to the same subject matter as was addressed in the course of prosecution, polynucleotides related to polynucleotide SEQ ID No. 2.

### ***Claim Rejections - 35 USC § 112, second paragraph.***

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claims 23-27 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which

applicant regards as the invention. The claims are directed to nucleic acid sequence "capable of reducing expression level". It is not identified expression level of what said nucleic acids are capable to reduce.

***Claim Rejections - 35 U.S.C. § 101/ 112-1***

The following is a quotation of the 35 U.S.C. § 101:

"Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter or any new and useful improvement thereof, may obtain a patent therefore, subject to the conditions and requirements of this title".

The following is a quotation of the first paragraph of 35 U.S.C. § 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

4. Claims 23-27 are rejected under 35 U.S.C. § 101 because the claimed invention lacks patentable utility due to its not being supported by either specific and/or substantial utility or a well established utility. The claimed subject matter is not supported by a specific, substantial, and credible utility because the disclosed uses are generally applicable to broad classes of this subject matter. In addition, further characterization of the claimed subject matter would be required to identify or reasonably confirm a "real world" use. The examiner does not find an adequate nexus between the evidence of record and the asserted properties of the claimed subject matter.

The invention as claimed is drawn to nucleic acids having from 95% to 100% identity to sequence SEQ ID No.2. Nucleic acid of SEQ ID No. 2 itself is not supported by a specific asserted utility, first, because the use claimed, "capable of reducing expression level" is neither specific nor substantial because it is not identified expression level of what the said nucleic acids are capable to reduce. Further, the uses disclosed in general for all nucleic acids (SEQ ID Nos. 1 to 304701) are not specific and are generally applicable to any nucleic acid. The specification states that the nucleic acid compounds may be useful as probes for assisting in the isolation of full-length cDNAs or genes which would be used to make protein and optionally further usage to make the corresponding antibodies, plants, gene mapping, isolation of homologous sequences, detection of gene expression, and for numerous other generic genetic engineering usages. These are non-specific uses that are applicable to nucleic acids in general and not particular or specific to the nucleic acid of SEQ ID No. 2 being claimed. Further, the claimed nucleic acid compounds are not supported by a substantial utility because no substantial utility has been established for the claimed subject matter. For example, a nucleic acid may be utilized to obtain a protein. The protein could then be used in conducting research to functionally characterize the protein. The need for such research clearly indicates that the protein and/or its function is not disclosed as to a currently available or substantial utility. A starting material that can only be used to produce a final product does not have substantial asserted utility in those instances where the final product is not supported by a specific and substantial utility. In this case none of the proteins that are to be produced as final products resulting from processes

Art Unit: 1631

involving claimed nucleic acid have asserted or identified specific and substantial utilities. The research contemplated by applicants to characterize potential protein products, especially their biological activities, does not constitute a specific and substantial utility. Identifying and studying the properties of a protein itself or the mechanisms in which the protein is involved does not define a "real world" context or use. Similarly, the other listed and asserted utilities are neither substantial nor specific due to being generic in nature and applicable to a myriad of such compounds. Note, because the claimed invention is not supported by a specific and substantial asserted utility for the reasons set forth above, credibility has not been assessed. Neither the specification as filed nor any art of record discloses or suggests any property or activity for the nucleic acid compounds such that another non-asserted utility would be well established for the compounds.

The instant situation is analogous to that which was addressed in *Brenner v. Manson*, 148 USPQ 689 (1966), wherein the court expressed the opinion that all chemical compounds are "useful" to the chemical arts when this term is given its broadest interpretation. However, the court held that this broad interpretation was not the intended definition of "useful" as it appears in 35 U.S.C. 101, which requires that an invention must have either an **immediately apparent** or fully disclosed "real world" utility (emphasis added).

The U.S. Court of Appeals for the Federal Circuit recently addressed the utility requirement in the context of a claim to DNA. See In re Fisher, 421 F.3d 1356, 76 USPQ2d 1225 (Fed. Cir. 2005). The Fisher court interpreted the above-discussed

Brenner v. Manson, 383 U.S. 519, 148 USPQ 689 (1966), as rejecting a “de minimis view of utility.” 421 F.3d at 1370, 76 USPQ2d at 1229. The Fisher court held that 101 requires a utility that is both substantial and specific. Id. At 1371, 76 USPQ2d at 1229. The court held that disclosing a substantial utility means “show[ing] that an invention is useful to the public as disclosed in its current form, not that it may be useful at some further date after further research.” Simply put, to satisfy the ‘substantial’ utility requirement, an asserted use must show that claimed invention has a significant and presently available benefit to the public.” Id., 76 USPQ2d at 1230.

The Fisher court held that none of the uses asserted by the applicant in that case were either substantial or specific. The uses were not substantial because “all of Fisher’s asserted uses represent merely hypothetical possibilities, objectives which the claimed ESTs, or any EST for that matter, could possibly achieve, but none for which they have been used in the real world.” Id. At 1373, 76 USPQ2d at 1231.

Accordingly, the claimed subject matter fails to satisfy the utility as required under 35 U.S.C. 101 for the above reasons.

5. Claim 23-27 are also rejected under 35 U.S.C. § 112, first paragraph. Specifically, since the claimed invention is not supported by either a specific and substantial asserted utility or a well established utility for the reasons set forth above, one skilled in the art would not know how to use the claimed invention. In addition, the claims address nucleic acids as “capable of reducing expression level”, without

identifying expression level of what said nucleic acids are capable to reduce. Thus, an artisan would not know how to make or use said invention.

***Claim Rejections - 35 USC § 112, first paragraph.***

6. Claims 23-27 are rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventors, at the time the application was filed, had possession of the claimed invention.

The specification discloses nucleic acids of SEQ ID No.2. Claims limited to nucleic acid of SEQ ID No.2 would meet the written description and enablement provisions of 35 U.S.C. §112, first paragraph. However, the claims are directed to nucleic acids comprising said SEQ ID No. 2 and thus encompass products such as full-length DNAs and genes. None of these sequences are described in the instant specification at the structural level. The specification provides insufficient specification for the genus encompassed by the claim.

Vas-Cath Inc. v. Mahurkar, 19 USPQ2d 1111, makes clear that "applicant must convey with reasonable clarity to those skilled in the art that, as of the filing date sought, he or she was in possession of *the invention*. The invention is, for purposes of the 'written description' inquiry, *whatever is now claimed*." (See page 1117.) The specification does not "clearly allow persons of ordinary skill in the art to recognize that [he or she] invented what is claimed." (See Vas-Cath at page 1116.)

With the exception of nucleic acids consisting of sequences of identified SEQ ID No. 2, the skilled artisan cannot envision the detailed chemical structure of the encompassed polynucleotides and/or proteins, regardless of the complexity or simplicity of the method of isolation. Adequate written description requires more than a mere statement that it is part of the invention and reference to a potential method for isolating it. The nucleic acid itself is required.

Therefore, only nucleic acids consisting sequence of identified SEQ ID No. 2, but not the full breadth of the claim meet the written description provision of 35 USC 112, first paragraph. The species specifically disclosed are not representative of the genus because the genus is highly variant.

7. Claims 23-26 are rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventors, at the time the application was filed, had possession of the claimed invention.

The claims are drawn to polynucleotides having at least 95% degree of identity with SEQ ID NO: 2. Polynucleotide SEQ ID No. 2 itself meets the written description and enablement provisions of 35 USC 112, first paragraph. However, claims 23-26 drawn to nucleotide sequences having from 95% to 100 % identity to SEQ ID 2, do not have sufficient description in the specification as description of species is insufficient to support a highly variable genus. Applicant is advised that absent factual evidence, a percentage sequence similarity of less than 100% over the entire length is not deemed

Art Unit: 1631


to reasonably support to one skilled in the art whether the biochemical activity of newly discovered sequence would be the same as that of similar known biomolecule. The effects of changes in the structure are largely unpredictable as to which ones have a significant effect versus not. Therefore, sequence similarity result in an unpredictable and therefore unreliable correspondence between the newly discovered sequence and a similar biomolecule of known function or expression. No sequence information indicating what is the necessary common attribute for the polynucleotides encompassed by the claimed genus to be useful in the detection of cancer are present in the specification. With the exception of SEQ ID NO: 2, the skilled artisan cannot envision the detailed chemical structure of the encompassed polynucleotides, regardless of the complexity or simplicity of the method of isolation. The species specifically disclosed are not representative of the genus because the genus is highly variant. Adequate written description requires more than a mere statement that it is part of the invention and reference to a potential method for isolating it. Describing a method of preparing a cDNA or even describing the protein that the cDNA encodes, as the example does, does not necessarily describe the cDNA itself. Accordingly, the specification does not provide a written description of the invention of claim 47-50. The specification provides insufficient written description to support the genus encompassed by the claim.

Therefore, only SEQ ID NO: 2 but not the full breadth of the claim meets the written description provision of 35 USC 112, first paragraph.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Michael Borin whose telephone number is (571) 272-0713. The examiner can normally be reached on 9am-5pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ardin Marschel, Ph.D., can be reached on (571) 272-0718. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

 Michael Borin, Ph.D.  
Primary Examiner  
Art Unit 1631

mlb